臨牀透析 Vol.28 No.13(5-2)


特集名 透析(腎代替療法)導入時期を考える
題名 慢性透析導入基準(1992) (2) 導入基準の現在 ― 意義と効果,限界と問題点
発刊年月 2012年 12月
著者 井関 邦敏 琉球大学医学部附属病院血液浄化療法部
【 要旨 】 1992年の厚生省基準では腎機能,臨床症状,および日常生活障害度3者の総合的評価(点数)によって透析導入を決定する.血清クレアチニン8mg/dL以上はしばしば用いられる末期腎不全(透析導入)の指標である.日本人の推定糸球体濾過量(eGFR)は血清クレアチニン4mg/dL以上であれば年齢・性に関わりなくほとんどがCKDステージ5の範疇である(日本腎臓学会編:CKD診療ガイド2012).腎不全による症状(尿毒症)は腎機能以外にeGFRの低下速度,原疾患,合併症など患者固有の条件によって異なる.IDEAL研究によってGFRを参考に導入時期を判断しても透析導入後の生存率に有意差がないことが証明された.
Theme Considering the timing of chronic dialysis (renal replacement therapy) initiation
Title Reappraisal of the criteria of starting dialysis treatment
Author Kunitoshi Iseki Dialysis Unit, University Hospital of the Ryukyus
[ Summary ] The 1992 Ministry of Health and Welfare criteria for chronic dialysis initiation were defined by scores of kidney function, clinical manifestations, and daily activity. High serum creatinine levels of 8.0 mg/dL or over are often regarded as indicators of terminal kidney failure. Patients with stage 5 CKD, or eGFR < 15mL/min/1.73 m2, are classified as end-stage kidney disease (ESKD) patients according to the definition of the KDIGO (Kidney Disease : Improving Global Outcomes) study. These patients are considered candidates for renal replacement therapy such as chronic dialysis therapy. Serum creatinine levels in CKD stage 5 patients are approximately 4.0mg/dL or higher, per the CKD practice guidelines of 2012 established by the Japanese Society of Nephrology. Uremic symptoms are analyzed in relation to the speed of GFR decline, primary kidney disease, and co-morbid conditions other than the degree of GFR. A recent IDEAL study exhibited that prognoses after initiating dialysis are not statistically different between patients who start dialysis early versus those who start later.
戻る